The López-Belmonte family increase their interest in ROVI to 63.1%

The majority shareholders of Laboratorios Farmacéuticos Rovi, S.A. increase their interest in ROVI to 35,383,462 shares


The López-Belmonte family, the principal shareholders of Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”), have increased their interest in the company’s share capital to 63.107% through their investment vehicle Norbel Inversiones, S.L., which has thus become the direct holder of 35,383,462 of ROVI’s shares.

Juan López-Belmonte Encina said: This increase in the interest held by Norbel Inversiones, S.L. in ROVI’s share capital reflects the López-Belmonte family’s clear bet on the company and our confidence in ROVI’s business model and its future prospects”.

No votes yet
 
Related
ROVI and Moderna Announce Collaboration for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a...
3 min
09/07/2020
ROVI reports operating revenue growth of 23% and EBITDA growth of 68%
Operating revenue increased by 23% to 101.0 million euros in the first quarter of 2020, mainly driven by the strength of the specialty...
7 min
13/05/2020